Gourary

John P. Gourary

Partner
New York
John Gourary is widely recognized as the leading practitioner in the highly specialized field of pharmaceutical royalty monetizations (both classic royalty monetizations and synthetic royalty monetizations). He has been involved in the royalty monetization market from its early stages, has advised on transactions with an aggregate value of over $10 billion, and has participated in virtually all of the landmark transactions in this unique area.
John is especially well known for his representations of major universities and non-profit institutions in their royalty monetizations.

John's clients have included Blackstone Life Sciences, Boston Children's Hospital, Canada Pension Plan Investment Board, Cold Spring Harbor Laboratory, Dana-Farber Cancer Institute, Dartmouth College, Duke University, Emory University, LifeArc, Northwestern University, Pfizer, Purdue Research Foundation (an affiliate of Purdue University), Sagard Healthcare Royalty Partners, Takeda, The Kennedy Trust for Rheumatology Research, The Walter and Eliza Hall Institute of Medical Research, University of Colorado, University of Newcastle upon Tyne,  and University of Pennsylvania.

John also has extensive experience with all kinds of bank finance transactions (including syndicated loans, acquisition finance, structured finance, and innovative financings of unusual asset classes).

Related Industries

Related Practices

Education

  • Columbia University, J.D. 1982, Editor, Columbia Law Review, Harlan Fiske Stone Scholar (1979-1982)
  • Princeton University, A.B. (Economics), magna cum laude, 1979

Bar and Court Admissions

BAR ADMISSIONS
  • New York

Experience

  • Representation of a leading US educational institution in the monetization of a portion of its royalty interests in a product for the treatment of an orphan disease.
  • Purdue Research Foundation (an affiliate of Purdue University) in the monetization of a portion of its royalty interests in Pluvicto for over $100 million
  • Two European non-profits in their monetization of a portion of their royalty interests in a pharmaceutical product for the treatment of certain seizures
  • A group of individual inventors affiliated with a US-based university in the monetization of their royalty interests in a pharmaceutical product for the treatment of certain cancers
  • LifeArc, a leading UK-based medical research charity, in two royalty monetizations, including its landmark monetization of a portion of its royalty rights in Keytruda for $1.297 billion (approximately £1 billion), the largest single-product royalty monetization ever done by a non-profit, and its sale of a small proportion of its royalty rights in Keytruda for $150 million (approximately £115 million)
  • University of Newcastle upon Tyne, a UK public research university, in its monetization of a portion of its royalty interests in Rubraca.
  • Cold Spring Harbor Laboratory, a leading not-for-profit research institute founded in 1890 and home to eight Nobel Prize winners, in its structured monetization of a portion of its royalty interests in the first product approved by the FDA for the treatment of a rare genetic disorder
  • Boston Children’s Hospital, one of the leading pediatric medical centers in the United States, in its monetization of a portion of its royalty interests in Vonvendi
  • The Walter and Eliza Hall Institute of Medical Research, Australia’s oldest medical research institute, in its monetization of a portion of its royalty interests in Venetoclax for up to U.S.$325 million (A$406 million), consisting of an up-front payment of U.S.$250 million and up to U.S.$75 million of additional payments upon the attainment of certain milestones, the largest royalty monetization by a non-profit institution outside the United States and the United Kingdom
  • Dana-Farber Cancer Institute, a world leader in cancer research, in two royalty monetizations, including its sale of a portion of its royalty interests in various Programmed Death Ligand-1 (PD-L1) cancer drugs for an up-front payment of $100 million and up to $68 million of additional payments upon the satisfaction of certain conditions
  • Group of Inventors associated with UCLA in connection with the sale by UCLA of royalty rights in respect of Xtandi for an up-front cash payment of $1.14 billion and potential additional payments based on future Xtandi sales, the largest royalty monetization done by an inventor group
  • Northwestern University, and an inventor affiliated with Northwestern University, in a series of royalty monetizations (structured both as sales and as financings through special purpose vehicles), including Northwestern’s 2007 sale of a portion of its worldwide royalty interests in Lyrica for $700 million
  • University of Pennsylvania in the structured sale of a portion of its worldwide royalty interests in Juxtapid
  • The Kennedy Trust for Rheumatology Research (a UK charitable trust which currently funds a major research institute at Oxford University) in the structured sale of a portion of its worldwide royalty interests in Remicade and Simponi, the first royalty monetization by a non-profit institution outside the United States
  • Duke University in the sale of a portion of its worldwide royalty interests in Myozyme and Lumizyme
  • University of Colorado in the structured sale of a portion of its worldwide royalty interests relating to certain uses of Botox
  • Emory University in a ground-breaking sale of its royalty interests in Emtriva for $540 million, the first royalty monetization conducted by auction and IDD’s 2005 Healthcare Deal of the Year
* - Mr. Gourary handled some of the above representations prior to joining Foley Hoag.
 

Honors & Involvement

HONORS
  • IAM Strategy 300 Global Leaders
  • IAM Strategy 300: The World’s Leading IP Strategists (2023, 2024)
  • New York Super Lawyers 
  • Who's Who in America
  • Who's Who in American Law

Contact Info

Subscribe

Stay Up to Date

Get the latest Foley Hoag news, publications, and event invitations.

Enter your email

We use cookies to enhance user experience, improve functionality and performance, and for analysis of website traffic. By clicking “accept”, you agree to the use of cookies. For more information about our cookie policy and the information we collect, please review our Privacy Statement.